The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The forever more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer - Pfizer (NYSE:PFE)
FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
Pembrolizumab regimens snag FDA nod for muscle-invasive bladder cancer
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval…
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a…
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3…
